UK markets closed
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • FTSE 250

    20,910.37
    -287.75 (-1.36%)
     
  • AIM

    1,183.25
    -8.61 (-0.72%)
     
  • GBP/EUR

    1.1532
    +0.0034 (+0.30%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • BTC-GBP

    32,286.89
    -1,971.05 (-5.75%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,786.29
    -93.04 (-0.67%)
     
  • CAC 40

    5,703.22
    -80.67 (-1.39%)
     

Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

·2-min read

Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

01-Feb-2021 / 22:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

Current Group expectations for FY/21
Based on the current status of the Group's financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth1 and at least broadly stable net income2 year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care's results and hence on Fresenius Group's net income2 growth.

Group medium-term targets
The current information and assumptions do not trigger a revision of Fresenius' medium-term growth targets, which were set before the COVID-19 pandemic emerged.

Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.

1 in constant currency
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programs

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., February 1, 2021

----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------

End of Note

01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg v.d.H.

Germany

Phone:

+49 (0)6172 608-2485

Fax:

+49 (0)6172 608-2488

E-mail:

ir-fre@fresenius.com

Internet:

www.fresenius.com

ISIN:

DE0005785604

WKN:

578560

Indices:

DAX

Listed:

Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange

EQS News ID:

1164992


 

End of Announcement

DGAP News Service

show this
show this